Literature DB >> 34273294

Lung cancer.

Alesha A Thai1, Benjamin J Solomon1, Lecia V Sequist2, Justin F Gainor2, Rebecca S Heist3.   

Abstract

Lung cancer is one of the most frequently diagnosed cancers and the leading cause of cancer-related deaths worldwide with an estimated 2 million new cases and 1·76 million deaths per year. Substantial improvements in our understanding of disease biology, application of predictive biomarkers, and refinements in treatment have led to remarkable progress in the past two decades and transformed outcomes for many patients. This seminar provides an overview of advances in the screening, diagnosis, and treatment of non-small-cell lung cancer and small-cell lung cancer, with a particular focus on targeted therapies and immune checkpoint inhibitors.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 34273294     DOI: 10.1016/S0140-6736(21)00312-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  156 in total

Review 1.  Prognostic value of myosteatosis in patients with lung cancer: a systematic review and meta-analysis.

Authors:  Shaofang Feng; Huiwen Mu; Rong Hou; Yunxin Liu; Jianjun Zou; Zheng Zhao; Yubing Zhu
Journal:  Int J Clin Oncol       Date:  2022-05-23       Impact factor: 3.402

Review 2.  Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer.

Authors:  Sun Ha Choi; Seung Soo Yoo; Shin Yup Lee; Jae Yong Park
Journal:  Arch Pharm Res       Date:  2022-04-21       Impact factor: 4.946

3.  c-myc-mediated upregulation of NAT10 facilitates tumor development via cell cycle regulation in non-small cell lung cancer.

Authors:  Zimu Wang; Yicong Huang; Wanjun Lu; Jiaxin Liu; Xinying Li; Suhua Zhu; Hongbing Liu; Yong Song
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

4.  Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.

Authors:  Xinhang Xia; Wenhu Pi; Yanli Lan; Xiaomai Wu; Dongqing Lv; Yinnan Meng; Haihua Yang; Wei Wang
Journal:  Anal Cell Pathol (Amst)       Date:  2022-06-16       Impact factor: 4.133

Review 5.  Targeted Therapy in Early Stage Non-small Cell Lung Cancer.

Authors:  Si-Yang Liu; Si-Yang Maggie Liu; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Curr Treat Options Oncol       Date:  2022-07-25

6.  Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3.

Authors:  Terry W Moody; Irene Ramos-Alvarez; Robert T Jensen
Journal:  Peptides       Date:  2022-08-03       Impact factor: 3.867

7.  Prognosis of different extrathoracic metastasis patterns in patients with M1c lung adenocarcinoma receiving immunotherapy.

Authors:  Fang Hu; Jin Peng; Xiaowei Mao; Yanjie Niu; Meili Ma; Yizhuo Zhao; Aiqin Gu; Liyan Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-27       Impact factor: 4.322

8.  18F-FDG PET/CT radiomics nomogram for predicting occult lymph node metastasis of non-small cell lung cancer.

Authors:  Jianyi Qiao; Xin Zhang; Ming Du; Pengyuan Wang; Jun Xin
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

9.  Transient targeting of BIM-dependent adaptive MCL1 preservation enhances tumor response to molecular therapeutics in non-small cell lung cancer.

Authors:  Kaixuan Shi; Haijiao Lu; Zhenfeng Zhang; Yujie Fu; Jie Wu; Shichao Zhou; Pengfei Ma; Kaiyan Ye; Shengzhe Zhang; Hailei Shi; Weiping Shi; Mei-Chun Cai; Xiaojing Zhao; Zhuang Yu; Jian Tang; Guanglei Zhuang
Journal:  Cell Death Differ       Date:  2022-09-28       Impact factor: 12.067

10.  Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.

Authors:  Jiaqi Li; Man Liu; Xue Zhang; Longtao Ji; Ting Yang; Yutong Zhao; Zhi Wang; Feifei Liang; Liping Dai
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-20       Impact factor: 4.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.